Krystal Biotech Q1 net loss $45.3M, cash $355.5M, PDUFA date May 19 for B-VEC

Krystal Biotech, Inc.

2023-Q1 EPS reported -$1.76

Net loss of $45.3M ($1.76 per share) vs $50.0M loss ($1.99) in Q1 2022.
Cash, equivalents & investments $355.5M at March 31, 2023.
R&D expense $12.3M (up from $9.3M); G&A expense $24.0M (up from $15.9M).
PDUFA date for B-VEC Biologics License Application is May 19, 2023; labeling discussions started in April.
Topical B-VEC in eye under compassionate use showed vision improvement from hand motion to 20/40 at 7 months.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Krystal Biotech, Inc. reported the quarter ended March 31, 2023 results: net income Net losses for the quarters ended March 31, 2023 and 2022 were $45.3 million and $50.0 million, or $(1.76) and $(1.99),, EPS $(1.76) and $(1.99), respectively, per common share (basic and diluted).

Period: the quarter ended March 31, 2023
Net income: Net losses for the quarters ended March 31, 2023 and 2022 were $45.3 million and $50.0 million, or $(1.76) and $(1.99),
EPS: $(1.76) and $(1.99), respectively, per common share (basic and diluted)
Result: reported results

Exact text from the filing

Net losses for the quarters ended March 31, 2023 and 2022 were $45.3 million and $50.0 million, or $(1.76) and $(1.99), respectively, per common share (basic and diluted).

View on SEC.gov

Browse all earnings releases →

Krystal Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001711279-23-000031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.